CNIPA.AI
Back to Search
Dossier

BIOMARKERS FOR DETERMINING A CANCER DISEASE STATE, RESPONSE TO IMMUNO-ONCOLOGY, STAGES OF FIBROSIS IN NON-ALCOHOLIC STEATOHEPATITIS, OR APPLICATION OF AGE OR SEX RELATED BIOMARKER PANEL FOR QUALITY CONTROL

InventionPending
29Claims · 14 independent
§ Ⅰ

Dossier Overview

Inventor

Chirag DHAR; Paul Oluwaseyi AIYETAN; Monil Dilip GANDHI; Alan Nicolas MITCHELL; Chad Eagle PICKERING; Prasanna RAMACHANDRAN; Daniel SERIE; Apoorva SRINIVASAN; Gege XU

IPC Classification

G16B 40/20G16H 10/40G16H 15/G16H 20/G16H 50/30

CPC Classification

G16B40/20G16H10/40G16H15/G16H20/G16H50/30

Provided herein are methods, devices, and kits for identifying glycosylated polypeptide biomarkers and signatures for progression of a disease or a condition, such as cancer or NASH, or and response of the disease or condition to a treatment. Also provided herein are: i) methods of generating and analyzing glycosylated polypeptide biomarkers, ii) methods of validating a model using glycosylated polypeptides for predicting the disease or condition or for making treatment recommendation, iii) systems and methods for implementing QC of a cohort of samples by analyzing peptide structure data for each sample using a machine learning model to generate a predicted age and/or sex associated for each sample. The quality control issue may include an error of mislabeled samples or an error from sample preparation, or a systemic measurement or an instrument error.

Original (Chinese)

Provided herein are methods, devices, and kits for identifying glycosylated polypeptide biomarkers and signatures for progression of a disease or a condition, such as cancer or NASH, or and response of the disease or condition to a treatment. Also provided herein are: i) methods of generating and analyzing glycosylated polypeptide biomarkers, ii) methods of validating a model using glycosylated polypeptides for predicting the disease or condition or for making treatment recommendation, iii) systems and methods for implementing QC of a cohort of samples by analyzing peptide structure data for each sample using a machine learning model to generate a predicted age and/or sex associated for each sample. The quality control issue may include an error of mislabeled samples or an error from sample preparation, or a systemic measurement or an instrument error.

External Resources